For the quarter ending 2026-03-31, STOK had $74,439K increase in cash & cash equivalents over the period. -$60,935K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net (loss) income | -50,003 | -57,934 | -38,348 | 89,397 |
| Depreciation | 439 | 405 | 442 | 923 |
| Amortization and accretion of marketable securities | -365 | -551 | -615 | 33 |
| Stock-based compensation expense | 8,753 | 9,848 | 8,039 | 14,351 |
| Impairment of right of use asset | - | 0 | 696 | - |
| Loss on disposal of property and equipment | - | -153 | 8 | - |
| Reduction in the carrying amount of right of use assets | 608 | 650 | 547 | 1,211 |
| Accounts receivable | -1,486 | -3,312 | 7,580 | - |
| Prepaid expenses and other current assets | 3,588 | -220 | -5,640 | 6,405 |
| Accounts payable, accrued liabilities and lease liabilities | -15,719 | 8,902 | 4,881 | 7,506 |
| Deferred revenue | -2,193 | 4,541 | -4,060 | -611 |
| Net cash (used in) provided by operating activities | -60,582 | -30,454 | -30,366 | 106,405 |
| Purchases of marketable securities | 9,853 | 98,228 | 23,925 | 200,569 |
| Purchases of property and equipment | 353 | 232 | 132 | 306 |
| Proceeds from maturity of marketable securities | 60,900 | 37,399 | 33,151 | 66,030 |
| Net cash used in investing activities | 50,694 | -61,061 | 9,094 | -134,845 |
| Proceeds from employee stock purchase plan | 465 | 0 | 632 | 370 |
| Proceeds from issuance of common stock upon exercise of stock options | 3,205 | 4,557 | 2,488 | 1,558 |
| Proceeds from controlled equity offering sales agreement, net of commissions | - | 87,784 | - | - |
| Proceeds from issuance of common stock in controlled equity offering sales agreements | 80,657 | - | - | - |
| Net cash provided by financing activities | 84,327 | 92,341 | 3,120 | 1,928 |
| Net increase in cash, cash equivalents and restricted cash | 74,439 | 826 | -18,152 | -26,512 |
| Cash, cash equivalents and restricted cashbeginning of period | 84,941 | 44,664 | 128,779 | - |
| Cash, cash equivalents and restricted cashend of period | 159,380 | 826 | 84,115 | - |
Stoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc. (STOK)